Talaris Therapeutics, Inc. (NASDAQ:TALS – Get Free Report) was the target of a significant decrease in short interest in the month of June. As of June 30th, there was short interest totalling 270,300 shares, a decrease of 71.7% from the June 15th total of 955,200 shares. Based on an average daily volume of 629,200 shares, […]
Short Interest in Talaris Therapeutics, Inc (NASDAQ:TALS) Decreases By 71 7% theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.
Talaris Therapeutics, Inc. (NASDAQ:TALS – Get Rating) Director Suzanne Ildstad sold 16,870 shares of the company’s stock in a transaction dated Monday, June 12th. The stock was sold at an average price of $2.59, for a total value of $43,693.30. Following the transaction, the director now directly owns 3,798,542 shares of the company’s stock, valued […]
Talaris Therapeutics, Inc. (NASDAQ:TALS – Get Rating) Director Suzanne Ildstad sold 12,942 shares of Talaris Therapeutics stock in a transaction dated Wednesday, June 14th. The shares were sold at an average price of $2.49, for a total value of $32,225.58. Following the completion of the transaction, the director now directly owns 3,771,392 shares in the […]
Talaris Therapeutics, Inc. (NASDAQ:TALS – Get Rating) Director Suzanne Ildstad sold 12,942 shares of the company’s stock in a transaction dated Wednesday, June 14th. The stock was sold at an average price of $2.49, for a total value of $32,225.58. Following the sale, the director now owns 3,771,392 shares in the company, valued at approximately […]